Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Gartrell

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
JAMA Network Open|November 12, 2021
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19Andrew L Schmidt, Matthew D Tucker, Ziad Bakouny, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
JAMA Network Open|November 12, 2021
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19Andrew L Schmidt, Matthew D Tucker, Ziad Bakouny, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Pageof 6